Glioblastoma is the most frequent and devastating primary malignant brain tumor in adults.
Surgery followed by standard radiotherapy with concomitant and adjuvant chemotherapy …

Despite treatment with the current standard-of-care therapies, patients with newly diagnosed
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …

Recurrent glioblastomas (rGBM) invariably relapse after initial response to anti-VEGF
therapy. There are 2 prevailing hypotheses on how these tumors escape antiangiogenic …

Purpose A phase II study of bevacizumab (BVZ) plus irinotecan (CPT-11) was conducted in
children with recurrent malignant glioma (MG) and intrinsic brainstem glioma (BSG). Patients …

High grade gliomas (HGG) are one of the most common central nervous system (CNS)
tumors encountered in adults, but they only represent approximately 8–12% of all pediatric …

Despite advances in upfront therapy, the prognosis in the great majority of patients with
glioblastoma (GBM) is poor as almost all recur and result in disease-related death …

Object The presence of angiogenesis is a hallmark of glioblastoma (GBM). Vascular
endothelial growth factor (VEGF), which drives angiogenesis, provides an additional target …

Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional
cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target …

Objective To perform a retrospective analysis examining the incidence and prognosis of
glioma patients with leptomeningeal disease (LMD) at Memorial Sloan Kettering Cancer …

Objective Diffuse intrinsic pontine gliomas (DIPGs) are highly aggressive tumors and have a
poor prognosis. Nearly all patients experience disease progression after definitive treatment …